Domain Therapeutics grants Prexton Therapeutics an exclusive option to license and develop mGluR4 PAMs for Parkinson’s disease

29-Jan-2013 - Switzerland

Domain Therapeutics S.A. announced that Domain Therapeutics grants Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease.

This agreement between Domain Therapeutics and Prexton Therapeutics - a spin-off company of Merck Serono formed around its R&D portfolio in the field of Parkinson’s disease - follows a strategic decision from Merck Serono to focus its research efforts on certain diseases such as multiple sclerosis, cancer and immune-mediated diseases.

Under the terms of the agreement signed between Domain and Prexton, Prexton will benefit from an exclusive license option to progress the mGluR4 PAM drug candidates into clinical development.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance